Cardio-metabolic and immunological impacts of extra virgin olive oil consumption in overweight and obese older adults: a randomized controlled trial by Rozati, M et al.
RESEARCH Open Access
Cardio-metabolic and immunological
impacts of extra virgin olive oil
consumption in overweight and obese
older adults: a randomized controlled trial
Mitra Rozati1,2, Junaidah Barnett1, Dayong Wu1, Garry Handelman2, Edward Saltzman1, Thomas Wilson2, Lijun Li1,
Junpeng Wang1, Ascensión Marcos3, José M. Ordovás1, Yu-Chi Lee1, Mohsen Meydani1 and
Simin Nikbin Meydani1*
Abstract
Background: Both aging and obesity are related to dysregulated immune function, which may be responsible for
increased risk of infection and also chronic non-infectious diseases. Dietary lipids have been shown to impact
immune and inflammatory responses and cardio-metabolic risk factors. No information on the impact of olive oil
on immune responses of overweight and obese older adults is available.
Objective: We aimed to determine the effect of replacing oils used in a typical American diet with extra virgin
olive oil for 3 months on immune responses and cardio-metabolic risk factors in overweight and obese older
adults.
Methods: This was a randomized, single-blinded and placebo-controlled trial in 41 overweight or obese
participants (aged ≥ 65) who consumed a typical American diet. Participants in the control (CON, n = 21) group
were provided with a mixture of corn, soybean oil and butter, and those in the olive oil (OO, n = 20) group, with
extra virgin olive oil, to replace substitutable oils in their diet. At baseline and 3 months, we measured blood
pressure, biochemical and immunological parameters using fasting blood, and delayed-type hypersensitivity (DTH)
skin response.
Results: Compared to the CON group, the OO group showed decreased systolic blood pressure (P < 0.05), a strong
trend toward increased plasma HDL-C concentrations (P = 0.06), and increased anti-CD3/anti-CD28 -stimulated T cell
proliferation (P < 0.05). No differences were found in T cell phenotype, cytokine production, and DTH response
between the two groups.
Conclusions: Our results indicate that substitution of oils used in a typical American diet with extra virgin olive oil
in overweight and obese older adults may have cardio-metabolic and immunological health benefits. This trial was
registered at clinicaltrials.gov as NCT01903304.
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Introduction
Olive oil, which is part of the Mediterranean diet (Med-
diet), has been shown to have several health benefits
including a capacity to lower the risk of cardiovascular
disease (CVD), stroke, and certain forms of cancer. The
health benefits of olive oil have been linked mostly to its
high content of oleic acid and phenolic compounds [1–4].
It is well known that aging is associated with dysregu-
lated immune function and increased susceptibility to
infectious diseases as well as higher incidence of non-
infectious diseases such as CVD, dementia, arthritis,
diabetes, cancer, and autoimmune disorders [5, 6].
Changes in both cell-mediated immunity and inflam-
matory responses have been reported with aging. While
age-associated changes are observed in almost all as-
pects of the immune system, a decline in T cell function
is believed to be the central defect in immunosenes-
cence [7–10]. Age-related decline in ex vivo antigen
and mitogen-stimulated T cell proliferation [11, 12] as
well as in vivo T cell responses to immunization [13],
and delayed-type hypersensitivity (DTH) skin response
[14] have been reported across all species. The decline
in T cell-mediated function is attributed somewhat to
phenotypic changes in lymphocytes [15–17], decline in
IL-2 production [18] and increase in production of T
cell suppressive eicosanoids [19, 20].
On the other hand, aging is associated with chronic in-
flammation as indicated by higher levels of inflammatory
markers such as IL-6 and tumor necrosis factor-alpha
(TNF-α), both of which may cause substantial tissue
damage and dysfunction [5, 21, 22] and are believed to
be key players in the pathogenesis of several diseases in-
cluding CVD, rheumatoid arthritis (RA), neurodegenera-
tive diseases, and cancer [23, 24].
Similar to aging, obesity is associated with low-grade,
chronic inflammation, which is thought to contribute
to the development of several inflammatory diseases
[25, 26]. Obesity is also shown to impair T cell function
and resistance to infection [26, 27]. Evidence in both
humans and mice has shown that metabolic tissues in
the obese (including adipose, liver, muscle, pancreas
and brain) compared to those in lean controls secrete
more inflammatory mediators/markers such as TNF-α,
IL-6 and C reactive protein [28–32]. Studies have
shown that increased adherence to the Med-diet
enriched by extra virgin olive oil (EVOO) is associated
with lower incidence of obesity [33, 34], hypertension
[35] and hyperlipidemia [36].
The limited studies conducted on the immuno-
modulatory effect of olive oil have shown inconsistent
results [37, 38]. Additionally, the majority of these stud-
ies have reported the anti-inflammatory and antioxidant
effects of olive oil [39–42] with little information avail-
able on the impact of olive oil on T cell-mediated
immune response in humans. Moreover, few studies
have evaluated olive oil’s effect on both T cell-mediated
function and inflammatory responses, and none of
them have been conducted in overweight or obese older
adults. Given that both obesity and aging are associated
with increased inflammation and impaired T cell function,
it is critical to determine the health benefits of olive oil in
this particular population. Further, all previous studies fo-
cusing on immune function have used refined olive oil ra-
ther than EVOO, which contains phenolic compounds
that have antioxidant properties not found in refined olive
oil. These components have been suggested to be key fac-
tors contributing to EVOO’s beneficial effects [1–3].
There is growing evidence that olive oil has some
beneficial effects on CVD through different mechanisms
including effects on lipid profile, blood pressure, inflam-
mation, and arterial wall function [35, 36, 43–45]; but to
our knowledge, none of those studies have been con-
ducted in overweight or obese older adults. Thus, the
current study was conducted to evaluate whether substi-
tuting oils in a typical American diet with EVOO would
improve T cell-mediated immune function and inflam-
matory responses as well as factors related to cardio-
metabolic status in overweight or obese older adults
such as lipid profile and blood pressure.
Subjects and methods
Participants
Participants for this study were recruited by the Recruit-
ment and Volunteer Services Department at the Jean
Mayer USDA Human Nutrition Research Center on
Aging (HNRCA) at Tufts University by inviting individ-
uals within the specified age and body mass index (BMI)
ranges in the HNRCA recruitment database, advertising
in various local newspapers, in media sources, at the
Tufts University Boston campus, Tufts Medical Center
clinics, and on public bulletin boards in the downtown
Boston area and neighboring towns. A total of 960 re-
sponses were received. After telephone pre-screening,
799 individuals were considered ineligible because they
either were no longer interested or did not meet study
criteria. Following laboratory screenings, an assessment
of medical history and a physical examination per-
formed by a study nurse practitioner in the Metabolic
Research Unit (MRU) at the HNRCA, an additional 117
of the remaining 161 individuals were found ineligible
to participate.
Subjects were excluded if they reported that they did
not speak English, were blind or deaf, were on a vegetar-
ian diet, ate more than 3 meals per week at a restaurant,
had chronic eating disorders, were HIV+, or had auto-
immune diseases or cancers (except for non-melanoma
skin cancer), used chemotherapy or immunosuppressive
drugs, or had any major illnesses including uncontrolled
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CVD, liver disease, renal disease, diabetes, hyperten-
sion, asthma, a history of splenectomy, were on dialysis
or had any conditions associated with maldigestion or
malabsorption including pancreatitis, celiac disease,
gastric bypass or surgery for weight loss. Additionally,
they were excluded if they were diagnosed with or were
in treatment for psychosis and had obtained a BDI-II
(Beck Depression Inventory-II) score ≥ 20 or MMSE
(Mini Mental State Examination) score ≤ 25. Finally,
they were excluded if they consumed more than 2
glasses of alcoholic drinks/day or had a history of smok-
ing; further, they were excluded if any of the following oc-
curred prior to study blood draws and skin tests: they had
used nicotine within 6 months, were on antibiotics or had
infections within 2 weeks, received flu vaccination within
3 weeks and tetanus immunization within 6 weeks.
Subjects of both genders were included if they were 65
y or older, had a BMI between 25–35 kg/m2, were will-
ing to stop using dietary supplements (except vitamin D
and calcium) including multivitamin and minerals, fish
oil, olive oil, and canola oil, 30 days before and during
the study. Additionally, they were consuming and were
required to continue consuming a typical American diet.
The diet composition of the typical American diet has
been determined by National Health and Nutrition
Examination Survey (NHANES) as follows: carbohy-
drates make up 50 % of daily energy requirements and
include refined and processed grain products, fruits and
vegetables and dairy products. Protein constitutes 15 %
of daily energy requirements provided from sources such
as meats and dairy products. Fat makes up 35 % of daily
energy requirements, which represents 86 g of fat/day in
a 2200 calorie diet. The fatty acid composition includes
polyunsaturated fatty acids (PUFA), saturated fatty acid
(SFA), and monounsaturated fatty acids (MUFA) at the
ratio of 1:2:2. Dietary fiber and cholesterol intake are
12–14 g/day and ≥400 mg/day, respectively [46, 47].
The forty-four subjects who were eligible to participate
in the study signed the informed consent form, and 41
participants completed the study. Three (3) participants
dropped out of the study: one was prescribed an iron
supplement, one refused to have DTH skin test implant,
and one had an accident unrelated to the study (Fig. 1).
Study design
We conducted a randomized, single-blinded, and
placebo-controlled trial in overweight and obese older
adults between 2011 and 2013 to determine the impact
of replacing substitutable oils in a typical American diet
with extra virgin olive oil. The study protocol and con-
sent form were approved by the Tufts University/Tufts
Medical Center Institutional Review Board. Eligible par-
ticipants were randomized into either the CON or OO
group in a 1:1 ratio.
The coding for the CON and treatment groups was
assigned by the study statistician, who had no contact with
subjects and had no role in data collection. The study oils
(CON or OO) were labeled with the subjects’ names by
the study dietitian, who also held the randomization code;
all other investigators and the study nurses were blinded
to this information. Participants, however, could not be
blinded since they might recognize the smell and taste of
EVOO.
The oils were provided in a bottle or as a spread. To
minimize bias, both study oils were provided to partici-
pants in the same type of bottle (oil) and the spread in the
same type of container (spread). The CON oil was a blend
of 10 % corn oil and 90 % soybean oil, and the CON
spread was butter; these were defined as the oils con-
sumed in a typical American diet [48]. The EVOO used
for the study was provided by the Deoleo Company in
Cordoba, Spain. Prior to screening, participants were
asked to taste the oil/spread and to confirm they were
willing to consume these oils while on the study (Table 1
shows the composition of fatty acids in both the CON and
OO groups).
Participants consumed the assigned oils for 3 months.
During the study, both groups continued their typical
American diet with only one change: they replaced sub-
stitutable oils in their diet (cooking oil, spread, and oils
in dressings) with the study oil/spread provided to them.
The study oils were distributed to the participants by the
dietitians at the MRU of the HNRCA.
Baseline and month 3 study visits
Subjects were asked to come to the center for 4 consecu-
tive days at the beginning (baseline) of the study and
3 months after enrollment. On day 1, vital signs
(temperature, blood pressure, pulse, and respiratory rate),
weight, height, and waist and hip circumferences were
measured. Subjects were asked to discontinue anti-
inflammatory medicines including aspirin or anti-
histamines 72-h before each blood collection until 48-h
after DTH implantation. On day one, blood was collected
after a 12-h fast for blood chemistry, lipid profile,
complete blood count (CBC) differential, fatty acids, and
immunological tests described below. On day 2, a second
blood sample was drawn for repeated ex vivo immune
tests. Then, three (3) recall antigens (detailed below) and
saline were implanted in the forearm of each subject for
the DTH skin test, as an in vivo test of cell-mediated im-
mune function [49]. On day 3 and 4, participants visited
the MRU for an evaluation of their DTH skin response at
24-h and 48-h post-administration, respectively.
Diet intervention visits and assessment of dietary intake
Dietitians at the MRU at HNRCA provided participants
with instructions for substituting fats used in their diets
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with study oils and spreads. Dietary counseling was pro-
vided every two weeks or more often as needed to en-
sure that all subjects were following the instructions,
were using the right oil and adhering to the appropriate
diet. Compliance with consuming study oils was evalu-
ated by the dietitians using a “checklist of study oils con-
sumed per week” as indicated by participants when they
returned used containers for a new supply of study oils
and spreads as well as by plasma fatty acid analysis (see
below). To assess dietary intake, participants completed a
3-day dietary record (3DDR) at both baseline and month
3, which were reviewed and analyzed by a dietitian using
the Minnesota Nutrient Data System (Nutrition Coordin-
ating Center, University of Minnesota, Minneapolis, MN),
version 2010.
CBC differential, blood chemistry, and blood lipid profile
Fasting blood was used for evaluation of CBC-differential
[50], blood glucose [51], and blood lipid profile [triglycer-
ides [52], total cholesterol [53], low density lipoprotein
cholesterol (LDL-C), and high density lipoprotein choles-
terol (HDL-C) [54] at baseline and month 3 by the Nutri-
tional Evaluation Laboratory (NEL) at the HNRCA.
Fatty acid analysis
Compliance of study oil intake was determined by meas-
uring fatty acid composition in the plasma of partici-
pants by gas chromatography (GC) method [55].
Immunological assessment
Lymphocyte phenotype To determine lymphocyte
phenotype, whole blood surface staining of different
white blood cell markers was done using fluorescent
antibodies (all from eBioscience, San Diego, CA) for
total T cells (CD3+), helper T cells (CD4+), cytotoxic T
cells (CD8+), naïve and memory subpopulations within
CD4 and CD8 T cells (determined by their combined
Table 1 Composition of fatty acids in control and olive oils/
spreads
Fatty acids Olive oil Control oil Butter (control spread)
%
C14:0 0.4 0.1 11.5
C16:0 13.5 10.9 36.2
C16:1 1.3 0 0
C18:0 2.4 4.4 15.1
C18:1n9 68.3 22.7 30.7
C18:1n7 3.2 1.4 1.9
C18:2n6 10 54.2 4.1
C18:3n6 0 0 0
C18:3n3 0.7 6.3 0.5
C20:1n9 0.3 0 0
C20:4n6 0 0 0
C20:5n3 0 0 0
C22:5n6 0 0 0
Fatty acids (%) in control and olive oil samples analyzed by gas
chromatography as described in method section
Excluded (n=916)
Assessment for eligibility
(n=960)
Randomized (n=44)
Enrollment
Control group (n=24)
Dropped from the study 
(n=3)
Received allocated
intervention (n=21)
Olive oil group (n=20)
Dropped from the study 
(n=0)
Received allocated
intervention (n=20)
Allocation
Follow up
Finished the intervention
(n=21)
Finished the intervention
(n=20)
Analysis
Analyzed
(n=21)
Analyzed
(n=20)
Fig. 1 Study profile for recruitment and enrollment
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expression of CD45RA, CD45RO, and CD62L), B cells
(CD19+), and natural killer T cells (CD3 +NK+). Isotype
staining was also done as the negative control. Flow cy-
tometric measurement was conducted using an Accuri
C6 flow cytometer (BD Biosciences, San Jose, CA). Data
were analyzed using Flowjo 7.6 software (TreeStar Inc.,
Ashland, OR).
Lymphocyte proliferation T cell proliferation was mea-
sured by [3H]-thymidine incorporation after stimulation
of whole blood culture with different stimuli described
below. To account for the day-to-day variability in ex
vivo immunological measurements, blood was collected
two times (day 1 and day 2), and the average of the two
measurements was used in statistical analysis. Heparin-
ized blood was diluted 1:10 (final v: v) with RPMI 1640
supplemented with 100 kU/L penicillin, 100 mg/L
streptomycin, 2 mmol/L L-glutamine, and 25 mmol/L
HEPES (Gibco Laboratories, Grand Island, NY). Diluted
blood was stimulated with T cell mitogen concanavalin
A (Con A, Sigma, St. Louis, MO) at 5, 25, and 50 mg/L,
or immobilized anti-CD3 (eBioscience) at 1, 5, and
10 mg/L and soluble anti-CD28 (1 mg/L), and incubated
in 96-well round-bottom cell culture plates for 72-h.
Cultures were pulsed with 0.5 μCi [3H]-thymidine dur-
ing the last 4-h of incubation. Cells were harvested onto
glass fiber mats using a Perkin Elmer cell harvester
(model No. C961961, Waltham, MA). Cell proliferation
was quantified as the amount of [3H]-thymidine incorp-
oration into DNA, which is determined by liquid scintil-
lation counting in a Perkin Elmer counter (model No.
2450–0060). T cell proliferation is expressed as count
per minute (cpm).
Cytokine and PGE2 production Heparinized whole
blood was diluted 1:4 (final v: v) with RPMI 1640. To de-
termine T cell cytokine IL-2 and IFN-γ production, di-
luted whole blood was stimulated with Con A (25 mg/L)
or immobilized anti-CD3 (5 mg/L) and soluble anti-
CD28 (1 mg/L) in 24-well plate for 48-h. In addition, we
also assessed the impact of olive oil on inflammatory re-
sponse. Diluted whole blood was stimulated with lipo-
polysaccharide (LPS) (1 mg/L) in 24-well plates for 24-h
to measure the production of pro-inflammatory cyto-
kines IL-6 and TNF-α as well as lipid inflammatory me-
diator PGE2 using ELISA.
For all cytokines including IL-2, IFN-γ, IL-6, and TNF-
α, reagents were from BD Bioscience. For PGE2, high
sensitivity enzyme immune assay (EIA) kit (ENZO Life
Science Inc, PA, USA) was used. Plates were read in a
micro-plate reader (BioTek, model No. EL808) and an-
alyzed by Gene5 software.
Delayed-type hypersensitivity (DTH) skin test Three
recall skin test antigens, Candida Albicans (Candin,
Allermed Laboratories Inc, San Diego, CA), Tetanus
Toxoid (Toxoid Adsorbed, Sanofi Pasture, CA), and Tri-
chophyton Mentagrophytes (Trichophyton, Allermed
Laboratories Inc, San Diego, CA) were injected intrader-
mally at separate sites on the volar surface of the fore-
arm. Saline (0.9 %) was used as the negative control.
Candida, Trichophyton and saline were injected in a
standard volume of 0.1 ml, and tetanus toxoid was
injected in a volume of 0.025 ml. Skin tests were read 24
and 48-h after antigens were applied; a test was consid-
ered positive if the skin induration was ≥ 5 mm.
Statistical analysis
The demographic characteristics and other variables of
interest of the participants in the CON versus OO group
were compared at baseline by using Student’s t-test or
Chi-square test. Paired t-test or nonparametric test was
performed to compare the measures at baseline and
month 3 within each group. Differences in outcome
measures of interest between the groups were deter-
mined using Analysis of Covariance (ANCOVA) control-
ling for their corresponding baseline levels, sex and age
or using non-parametric test. We used log transform-
ation for the data that were not normally distributed.
Two-sided significance at P < 0.05 was considered to be
significant. Analyses were performed using IBM SPSS
Statistics version 21.
Results
Assessment of dietary and macronutrients intake
The average amount of study oil and spread consumption
was similar in the CON and the OO group (Table 2). We
assessed compliance by conducting both dietary assess-
ment (Table 3) and plasma fatty acid analysis (Table 4).
No difference was found in macronutrient intake at base-
line between groups. The OO group showed an increase
of total monounsaturated fatty acids (MUFA) (P < 0.001)
and oleic acid (P < 0.001) consumption compared to the
Table 2 Study oil intake of the study subjectsa
Control oil group Olive oil group
Intake (N = 19) (N = 18) P*
Provided oil/spread (g/day) 41 ± 8 39 ± 7 0.34
Energy (Kcal/day) 338 ± 69 347 ± 61 0.41
Total fat (g/day) 38 ± 8 39 ± 7 0.41
Total SFA (g/day) 11 ± 2 5 ± 1 <0.05
Total MUFA (g/day) 9 ± 2 29 ± 5 <0.05
Total PUFA (g/day) 17 ± 4 4 ± 1 <0.001
Abbreviations: SFA saturated fatty acids, MUFA Monounsaturated fatty acids,
PUFA Polyunsaturated fatty acids
* P-value was obtained by unpaired t-test
a Values are mean ± SEM
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CON group, and the CON group had increased polyunsat-
urated fatty acids (PUFA) intake (P < 0.05) compared to
the OO group after 3 months. No difference in intake of
other macronutrients including total fat, carbohydrates,
protein, fiber, and energy was observed between the
groups after 3 months.
Plasma fatty acid analysis (Table 4) indicated that par-
ticipants in the OO group had increased plasma oleic
acid (P < 0.05), total MUFA (P < 0.05), and oleic acid/
PUFA ratio (P < 0.05) compared to the CON group after
3 months. In addition, there was a reduction in total
plasma PUFA in the OO group compared to the CON
group after 3 months (P < 0.05).
Demographic, anthropometrics, blood pressure, blood
chemistry, and lipid profile
There was no significant difference in age, gender and
race between the two groups at baseline (Table 5). We
observed a reduction in systolic blood pressure in the
OO group compared to the CON group (P < 0.05) after
3 months (Table 5). There was no difference in other an-
thropometric measures between the two groups at base-
line or after 3 months of intervention. In addition,
participants in the OO group showed a trend (P = 0.06)
toward an increase in plasma HDL-C levels compared to
the CON group after 3 months (Table 5). No difference
was found in other parameters of lipid profiles tested in-
cluding total cholesterol, LDL-C, and triglycerides as
well as in blood glucose concentration between the two
groups at month 3.
Immunological assessments
CBC-differential and lymphocyte phenotypes No dif-
ference was found in total number of white blood cells,
percent or total number of lymphocytes, monocytes, neu-
trophils, eosinophils, and basophils at baseline or after
3 months of intervention between the two groups (data
are not shown). There was no difference in the changes
between the two groups in any of the blood lymphocyte
phenotypes measured over 3 months (Table 6).
Lymphocyte proliferation We found significant in-
crease in T cell proliferation in response to anti-CD3/
Table 3 Dietary intake of overweight and obese older adults in control and olive oil groups at baseline and month 3a
Control (N = 19) Olive Oil (N = 18)
Intake/day Baseline Month 3 Baseline Month 3 P*
Energy intake (Kcal) 1921 ± 130 1956 ± 142 1781 ± 128 2032 ± 104 0.31
Carbohydrate (g) 231 ± 17 217 ± 18 221 ± 21 225 ± 19 0.51
Carbohydrate (% Kcal) 47 ± 1 43 ± 2 47 ± 2 43 ± 2 0.75
Protein (g) 78 ± 6 72 ± 6 75 ± 5 82 ± 6 0.16
Protein (% Kcal) 17 ± 1 15 ± 1 17 ± 1 16 ± 1 0.31
Total dietary fiber 23 ± 3 22 ± 3 22 ± 3 22 ± 2 0.72
Fat (g) 77 ± 7 91 ± 9 68 ± 6 90 ± 6 0.66
Fat (% Kcal) 35 ± 1 41 ± 3 34 ± 3 39 ± 2 0.79
Total SFA (g) 23 ± 2 28 ± 3 23 ± 2 25 ± 2 0.33
Total MUFA (g) 28 ± 3 29 ± 3 24 ± 2 44 ± 4 <0.001
C18:1n9 (g) 27 ± 3 27 ± 3 23 ± 2 42 ± 4 <0.001
Total PUFA (g) 20 ± 2 28 ± 4 16 ± 2 15 ± 1 0.02
Abbreviations: MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, SFA saturated fatty acid
*P-value for difference between two groups was obtained by ANCOVA adjusting for age, sex and baseline value
aValues are mean ± SEM
Table 4 Plasma fatty acids of overweight and obese older
adults in control and olive oil groups at baseline and month 3a
Control (N = 20) Olive Oil (N = 20)
Fatty Acids Baseline Month 3 Baseline Month 3 P*
%
C18:1n9 (OA) 19 ± 1 18 ± 1 19 ± 1 20 ± 1 0.04
Total n-3 5 ± 1 5 ± 1 4 ± 0.3 4 ± 0.3 0.38
Total n-6 43 ± 1 42 ± 1 43 ± 1 41 ± 0.3 0.31
Total PUFA 47 ± 1 47 ± 1 47 ± 1 45 ± 1 0.04
Total MUFA 22 ± 1 22 ± 1 22 ± 1 24 ± 1 0.04
Total SFA 31 ± 0.4 31 ± 1 31 ± 1 32 ± 1 0.47
OA/PUFA (ratio) 0.4 ± 0.02 0.4 ± 0.02 0.4 ± 0.02 0.5 ± 0.02 0.03
n-6/n-3 (ratio) 13 ± 1 12 ± 1 12 ± 1 12 ± 1 0.58
ALA 0.6 ± 0.03 0.6 ± 0.04 0.6 ± 0.04 0.6 ± 0.1 0.45
Abbreviations: ALA alpha linolenic acid, MUFA monounsaturated fatty acids, OA
oleic acid, PUFA polyunsaturated fatty acids, SFA saturated fatty acids
*P-value for difference between two groups was obtained by ANCOVA
adjusting for age, sex and baseline value
aValues are mean ± SEM
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anti-CD28 (1 mg/L) after 3 months in the OO group
compared to the CON group (P < 0.05). There was no
difference in T cell proliferation in response to Con A
between the two groups (Table 7).
Cytokine production No difference was found in T cell
cytokine and pro-inflammatory cytokine production be-
tween the two groups after 3 months of intervention
(Table 8). There was heterogeneity in the change of
plasma oleic acid concentrations following intervention
in both groups. For the CON group, the range of change
in plasma oleic acid was between −5.14 and 3.15 %; in
the OO group, the range of change was between −3.84
and 7.32 %. This may be partly due to inter-individual
variability in endogenous oleic acid production and dif-
ference in compliance. As such, we ranked the change in
blood oleic acid levels between baseline and month 3 in
all participants in quintiles and evaluated the change in
cytokine levels between baseline and month 3 in relation
to the quintiles 1 and 5 of plasma oleic acid changes.
We found that participants who had the highest quintile
of oleic acid changes had a higher increase in IL-2 pro-
duction compared to the participants in the lowest quin-
tile (P < 0.01) (Fig. 2). No such association with other
cytokines was noted.
Delayed-type hypersensitivity skin test (DTH) Both
the CON and OO groups showed an increase in the
diameter of skin induration after 24 and 48-h of DTH
implant at month 3 compared to baseline, but the in-
crease was similar between the two groups (Table 9).
Discussion
To our knowledge, our study is the first comprehensive
one to determine the impact of substituting extra virgin
olive oil for the cooking oils used in a typical American
diet on cardio-metabolic and immunological outcomes
in overweight and obese older adults, a population at
higher risk for infectious and non-infectious chronic dis-
eases. We showed that consumption of extra virgin olive
oil for 3 months reduced blood pressure, tended to in-
crease plasma HDL-C levels, and improved T cell prolif-
eration. Further, participants in both groups with the
highest change in plasma oleic acid showed higher in-
crease in IL-2 production. There was no effect on other
blood lipids, glucose, and inflammatory mediators.
In agreement with the previous studies [35, 56–59],
we observed a blood pressure-lowering effect of EVOO
consumption. However, our observation is particularly
important because the participants, obese and older
adults, are at higher risk compared to lean younger
adults for developing cardiovascular disease. Furthermore,
since lower blood pressure is a predictor of survival and
freedom from physical and cognitive impairment [60],
Table 5 Demographic, anthropometric and cardio-metabolic
measures of overweight and obese older adults in control and
olive oil groups at baseline and month 3a
Control (N = 21) Olive Oil (N = 20)
Measures Baseline Month 3 Baseline Month 3 P*
Age (y) 72 ± 1 72 ± 1 0.77
Female, [n (%)] 15 (71) 12 (60) 0.52
Caucasian, [n (%)] 15 (71) 13 (65) 0.57
Weight (Kg) 80 ± 2 80 ± 2 80 ± 3 80 ± 3 0.39
Height (m) 1.7 ± 0.02 1.7 ± 0.02 1.7 ± 0.02 1.7 ± 0.02 N/A
BMI (Kg/m2) 29 ± 1 29 ± 1 29 ± 1 29 ± 1 0.31
Waist (cm) 97 ± 2 97 ± 2 97 ± 3 97 ± 3 0.96
Hip (cm) 106 ± 2 107 ± 2 106 ± 2 106 ± 2 0.10
DBP (mmHg) 76 ± 2 73 ± 2 76 ± 2 73 ± 1 0.99
SBP (mmHg) 126 ± 2 126 ± 3 128 ± 3 122 ± 2 0.04
Glucose (mg/dl) 102 ± 2 105 ± 2 101 ± 2 104 ± 2 0.86
HDL-C (mg/dl) 53 ± 2 52 ± 2 52 ± 3 54 ± 3 0.06
LDL-C (mg/dl) 144 ± 7 145 ± 7 130 ± 7 132 ± 6 0.39
TG (mg/dl) 104 ± 10 110 ± 11 103 ± 9 113 ± 13 0.69
Abbreviations: BMI body mass index, DBP diastolic blood pressure, HDL-C high
density lipoprotein-cholesterol, LDL-C low density lipoprotein cholesterol, SBP
systolic blood pressure, TG triglycerides, N/A not applicable
* P-value between groups was obtained by student (un-paired) t-test or
chi-square (demographic measures) or ANCOVA adjusting for age, sex and
baseline value (anthropometric and cardio-metabolic measures)
a Values are mean ± SEM or n (%)
Table 6 Lymphocyte phenotypes of overweight and obese
older adults in control and olive oil groups at baseline and
month 3a
Control (N = 15) Olive Oil (N = 16)
Cell type Baseline Month 3 Baseline Month 3 P*
%
Total CD4+ 53 ± 3 56 ± 2 53 ± 3 56 ± 3 0.92
Total CD8+ 16 ± 2 15 ± 2 16 ± 2 15 ± 2 0.45
CD4 naïve 34 ± 3 32 ± 4 31 ± 5 30 ± 5 0.82
CD4-CM 42 ± 2 44 ± 2 35 ± 5 38 ± 5 0.99
CD4-EM 19 ± 1 19 ± 1 16 ± 2 16 ± 2 0.77
CD4-TEM 6 ± 1 5 ± 1 5 ± 1 4 ± 1 0.31
CD8 naïve 25 ± 3 27 ± 3 30 ± 4 30 ± 4 0.45
CD8-CM 8 ± 1 8 ± 1 7 ± 1 9 ± 1 0.31
CD8-EM 14 ± 1 15 ± 1 12 ± 2 14 ± 2 0.39
CD8-TEM 50 ± 3 51 ± 3 49 ± 4 47 ± 5 0.42
CD3+ 63 ± 3 62 ± 3 60 ± 3 59 ± 4 0.77
CD19+ (B cell) 15 ± 2 15 ± 1 14 ± 2 14 ± 1 0.67
NKT cell 10 ± 1 10 ± 1 10 ± 1 13 ± 2 0.20
Abbreviations: CM central memory, EM effector memory, TEM terminal effector
memory, NKT natural killer T cell
*P-value for difference between groups was obtained by ANCOVA adjusting
for age, sex and baseline value
aValues are mean ± SEM
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both of which increase with age, our results support the
notion that consumption of EVOO may have the potential
to extend health span and curb development of age-
related diseases.
We observed a trend toward increased blood concen-
trations of HDL-C after olive oil consumption, which
supports the earlier reports of a beneficial effect of olive
oil on blood lipid profiles by Marrugat et al. [61]. The
less pronounced effect observed in our study compared
to theirs might be related to the difference in adminis-
tering olive oil between the two studies. Throughout
their study, subjects were provided with a daily dose of
25 mL of raw virgin olive oil and were directed to re-
place all other cooking fats with refined olive oil. In our
study, EVOO was provided to the subjects to use as they
wished (reflecting their actual lifestyle); therefore, they
might have consumed less uncooked olive oil. Given that
heating EVOO might destroy some of its active phenolic
compounds [62, 63], it is possible that subjects in Mar-
rugat’s study consumed more uncooked virgin olive oil,
and thus, higher levels of phenolic compounds, which
might have resulted in a more profound effect on their
plasma HDL-C levels.
Limited information is available about the impact of
olive oil on immune and inflammatory responses, and
no studies have used outcome variables as specific and
comprehensive as those in our current study or in any
study of overweight and obese older adults. For example,
a study by Yaqoob et al. showed no effect on T cell pro-
liferation in healthy middle-aged men (45–64 y, BMI
21.9–30.7) after they consumed only refined olive oil for
8 weeks [37]. This is in contrast to our observation that
extra virgin olive oil consumption resulted in a modest
improvement in T cell proliferation as well as an associ-
ation between an increased production of T cell cytokine
IL-2 and the magnitude of increase in plasma oleic acid.
The difference between our findings and those of
Yaqoob et al. [37] might be related to the fact that the
participants in our study were 65 y or older, while the
age range in their study was 45–64 y. It is reasonable to
assume that T cell function in the participants of our
study might have been less vigorous due to our subjects’
more advanced ages compared to those in the study by
Yaqoob et al. [37], possibly explaining the discrepancy
between the results of the two studies. This speculation
is also supported by the observation that a study
Table 7 Proliferative response of T cells to Con A and anti-CD3/anti-CD28 of overweight and obese older adults in control and olive
oil groups at baseline and month 3
Control (N = 21) Olive Oil (N = 20)
Stimulation condition Baseline Month 3 Baseline Month 3 P*
cpm x 103
Con A-5 mg/L 21 ± 5 24 ± 3 18 ± 3 21 ± 4 0.93
Con A-25 mg/L 31 ± 7 41 ± 5 31 ± 4 39 ± 5 0.61
Con A-50 mg/L 23 ± 5 28 ± 3 21 ± 3 31 ± 4 0.48
Anti-CD3/anti-CD28-1 mg/L 23 ± 5 22 ± 5 19 ± 4 29 ± 4 0.02
Anti-CD3/anti-CD28-5 mg/L 33 ± 7 35 ± 5 32 ± 5 40 ± 5 0.17
Anti-CD3/anti-CD28-10 mg/L 33 ± 7 36 ± 5 31 ± 5 41 ± 5 0.19
Abbreviations: Con A concanavalin A, cpm counts per minute
*P-value for difference between groups was obtained by ANCOVA adjusting for age, sex, and baseline value
Table 8 Cytokine concentrations of overweight and obese older adults in control and olive oil groups at baseline and month 3a
Control (N = 21) Olive Oil (N = 20)
Variables Baseline Month 3 Baseline Month 3 P*
pg/ml
IL-6 28159 ± 2555 26695 ± 3141 28798 ± 2217 30394 ± 3285 0.25
PGE2 5264 ± 802 4218 ± 562 3768 ± 605 3593 ± 3593 1.00
TNF-α 1878 ± 269 1806 ± 242 1720 ± 295 1785 ± 200 0.31
IL-2-CD3 218 ± 40 195 ± 41 209 ± 33 236 ± 46 0.73
IL-2-Con A 5709 ± 903 5553 ± 836 6073 ± 690 5500 ± 570 0.78
IFN-γ-CD3 7913 ± 1483 7718 ± 1474 5298 ± 1501 7146 ± 1922 0.11
IFN-γ-Con A 16648 ± 2857 13910 ± 3232 15530 ± 3090 14551 ± 2847 0.20
Abbreviations: Con A cancanavalin A, IFN-γ interferon gamma, IL-6 interleukin-6, IL-2 interleukin-2, PGE2 prostaglandin E2, TNF-α tumor necrosis factor-alpha
*P-value for difference between groups was obtained by ANCOVA adjusting for age, sex, and baseline value
aValues are mean ± SEM
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conducted in patients with rheumatoid arthritis, who are
known to have reduced T cell-mediated function [64, 65],
showed that olive oil increased T- lymphocyte prolifera-
tion in peripheral blood mononuclear cells (PBMC) [38].
Additionally, in our study, we used EVOO, which has a
higher content of phenolic compounds and might have
caused a different effect compared to the refined olive oil
used in the study by Yaqoob et al. [37]. Furthermore, the
duration of the two studies differed–our study was 12-
weeks, their study was 8-weeks. This variation may have
also contributed to the difference in findings between the
two studies.
To determine the mechanism of olive oil-induced en-
hancement in anti-CD3/anti-CD28-induced T cell pro-
liferation, we evaluated the production of IL-2, the key
cytokine involved in the activation of T cells. When
assessing the entire group, we found no difference in
IL-2 production between the two study groups; how-
ever, since the range of change in plasma oleic acid in
the subjects who consumed olive oil (−3.84 % to
7.32 %) and control oil (−5.14 % to 3.15 %) was large,
we explored the relationship between quintiles of
change in IL-2 production and those in plasma oleic
acid in all subjects. Participants with the largest change
in plasma oleic acid levels, i.e., those in quintile 5,
showed a highly significant increase in IL-2 production
compared to those with the lowest change in plasma
oleic acid levels, i.e., those in quintile 1. These data sug-
gest that the increase in T cell proliferation might be
partly due to an oleic acid-induced increase in IL-2
production. However, further investigation is needed to
confirm this finding. Furthermore, our data indicate
that the olive oil-induced enhancement in T cell prolifera-
tion is not due to changes in blood composition of lym-
phocytes or T cell profiles as we did not find any
difference in the percent of lymphocytes or T cell pheno-
type profiles between the two groups after 3 months.
It is noteworthy that the effect of olive oil on T cell
proliferation in our study may be stimulation-specific
because enhanced T cell proliferation was found when
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Fig. 2 Association between changes in plasma oleic acid content (%) and IL-2 production (all participants). The percent changes in plasma oleic
acid were ranked in 5 quintiles, Q1 (−5.14 to-2.68); Q2, (−2.69 to −0.35); Q3, (−0.18 to 0.5); Q4, (0.89 to 2.66), and Q5, (2.78 to 7.32); N = 8 partici-
pants in each quintile. The change in IL-2 production in response to anti-CD3/anti-CD28 after 3 months is shown in Q1 and Q5. * Significantly dif-
ferent from Q1 by ANCOVA adjusting for age, sex and the baseline values of oleic acid and IL-2 at P < 0.01
Table 9 Delayed-type hypersensitivity skin test of overweight and obese older adults in control and olive oil groups at baseline and
month 3a
Control (n = 21) Olive Oil (N = 20)
Measurement Baseline Month 3 P* Baseline Month 3 P* P**
mm
Induration to candida 9.4 ± 2.1 13.5 ± 2.4 0.04 9.9 ± 1.9 11.8 ± 2.7 0.13 0.48
Induration to TT 14.6 ± 1.7 16.0 ± 2.5 0.57 10.2 ± 1.9 11.5 ± 1.9 0.73 0.32
Induration to TM 2.6 ± 1.2 4.0 ± 2.5 0.15 4.3 ± 1.6 6.7 ± 2.3 0.07 0.81
Total induration 26.6 ± 2.7 33.5 ± 3.9 0.03 24.4 ± 3.3 30.0 ± 4.4 0.04 0.37
No. of positive responses 1.66 1.86 0.16 a 1.79 1.74 0.74 b 0.08 b
Abbreviations: TT tetanus toxoid, TM trichophyton mentagrophytes
*P-value within group was obtained by paired t-test or nonparametric test as indicated by b under P* column
**P-value for difference between groups was obtained by ANCOVA or nonparametric test as indicated by b under P** column
aValues are mean ± SEM or (n) of measurements 48 h after administration of DTH
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anti-CD3/anti-CD28 Abs (TCR activation together with
co-stimulation), but not when T cell mitogen Con A,
was used to activate T cells. Although mechanisms of
signaling pathways were not the subject of our current
study, this finding implies that specific signaling path-
ways or lipid/protein microenvironment involved in T
cell receptor activation and co-stimulation-induced T
cell activation might be influenced by olive oil.
In contrast to a moderate effect on T cell proliferation,
olive oil consumption showed no effect on DTH skin
test, an in vivo marker for recall antigen-specific cell-
mediated immunity. Given that both groups showed an
increase in total diameter of induration, it is possible
that the boosting effect of repeated administration of the
skin test might have masked any additional effect of
olive oil.
There are some limitations to this study. First, since
participants were given oil/spread for ad libitum use in
their cooking at home, which allowed them to share
with their families, it was difficult to determine the exact
amount they themselves actually consumed even though
their average use was measured using a 3DDR. Second,
for those who used the oil for frying, only some of the
oil absorbed by the food was expected to be ingested.
The plasma fatty acid analysis reflected this situation
since it showed a moderate 2 % increase with a wide
range (−3.84 % to 7.32 %) in plasma oleic acid levels
after 3 months in the olive oil group compared to the
control group.
Nevertheless, based on significant changes in plasma
oleic acid as well as the information recorded by 3DDR,
both groups (OO and CON) were compliant to the
treatments. We are aware that measuring blood levels of
phenolic compounds present in olive oil could have en-
hanced compliance validation and data interpretation.
However, in the current study, the participants used the
oils at home at different times, thus a pre-determined
time between olive oil consumption and blood collection
could not be tightly controlled. Given that these phen-
olic compounds are metabolized over time after absorp-
tion, it would be unreliable to use random blood sample
to assess phenolic compounds following olive oil con-
sumption [66].
In conclusion, our findings suggest that substituting
EVOO for oils used in a typical American diet may have
both cardio-metabolic and immunologic health benefits
as indicated by reduced systolic blood pressure, a strong
trend toward increased plasma HDL-C, and a moderate
enhancing effect on T cell-mediated function. However,
our results do not support an anti-inflammatory effect
of EVOO in obese older adults. Given the increased risk
of high blood pressure and a decline in T cell-mediated
function in older adults, particularly those who are over-
weight and obese, our results suggest that overweight
and obese older adults might benefit from substituting
the oils used in their typical American diet with extra
virgin olive oil.
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